15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering BioXcel Therapeutics Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $4.00 to $17.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.67 sits 1056% above the current $0.75. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.72 next quarter toward $-1.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to BioXcel Therapeutics Inc.
As of Aug, 2 of 3 firms rate BTAI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BTAI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.72
Range $-0.72 – $-0.72 · 1 analysts
Next period, 1 analysts expect BioXcel Therapeutics Inc to earn $-0.72 a share (range $-0.72 – $-0.72), versus — a year earlier. Full-year consensus is $-2.70, growing to $-1.57 the year after.
REVENUE · NEXT QUARTER
$190.5K
Range $190.5K – $190.5K · 1 analysts · -26% YoY
Revenue is expected to reach $190.5K (range $190.5K – $190.5K), -25.6% year-over-year. Full-year consensus is $769.9K, rising to $18.9M next year.
Top analysts covering BioXcel Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BTAI.
#1
Sumant Kulkarni
Canaccord Genuity · Rank #287
Buy
$18.00+2301.9% to target
Overall win rate
41%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #294
Buy
$5.00+567.2% to target
Overall win rate
37%
+ Follow
#3
Elemer Piros
Lucid Capital
Buy
No targeton BTAI
Coverage
—
+ Follow
#4
MK
Michael King
Rodman & Renshaw
Buy
$17.00+2168.5% to target
Coverage
—
+ Follow
#5
Graig Suvannavejh
Mizuho
Hold
$4.00+433.8% to target
Coverage
—
+ Follow
BTAI stock forecast FAQ
What is BTAI's average 12-month price target?+
The 3 analysts with a live target average $8.67 for BioXcel Therapeutics Inc over the next 12 months, ranging from a $17.00 high to a $4.00 low.
Is BTAI stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BTAI?+
The Street-high target is $17.00 (Rodman & Renshaw), and the Street-low is $4.00 (Mizuho). The average of all 3 active targets is $8.67.
How many Wall Street analysts cover BTAI?+
3 analysts have an active rating on BioXcel Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering BTAI?+
Among analysts who currently cover BTAI, Sumant Kulkarni of Canaccord Genuity has the strongest overall Quantellect track record (Rank #287). Their current call is Buy with a $18.00 target.
What is BioXcel Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.72 per share (range $-0.72 – $-0.72) across 1 analysts. Full-year EPS is projected at $-2.70, rising to $-1.57 the following year.
How much revenue is BioXcel Therapeutics Inc expected to report next quarter?+
Consensus revenue is $190.5K (range $190.5K – $190.5K). Full-year revenue is projected at $769.9K, growing to $18.9M next year.
Have analysts been upgrading or downgrading BTAI lately?+
As of Aug, 2 of 3 firms rate BTAI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BTAI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
